World Health Org Calls for Early Treatment for Everyone with HIV

Everyone with HIV should be given antiretroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the WHO said

Illustration of retroviruses.

©iStock.com

Join Our Community of Science Lovers!

By Stephanie Nebehay

GENEVA (Reuters) - Everyone with HIV should be given antiretroviral drugs as soon as possible after diagnosis, meaning 37 million people worldwide should be on treatment, the World Health Organization (WHO) said on Wednesday.

Recent clinical trials have confirmed that early drug use extends the lives of those with HIV and cuts the risk of disease transmission to partners, the WHO said in a statement setting out the new goal for its 194 member states.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Under previous WHO guidelines, which limited treatment to those whose immune cell counts had fallen below a certain threshold, 28 million people were deemed eligible for antiretroviral therapy (ART).

All people at "substantial" risk of contracting HIV should also be given preventive ART, not just men who have sex with men, the WHO said.

The new guidelines are a central plank of the United Nations agency's aim to end the AIDS epidemic by 2030.

"Everybody living with HIV has the right to life-saving treatment. The new guidelines are a very important step towards ensuring that all people living with HIV have immediate access to antiretroviral treatment," said Michel Sidibe, executive director of UNAIDS.

"According to UNAIDS estimates, expanding ART to all people living with HIV and expanding prevention choices can help avert 21 million AIDS-related deaths and 28 million new infections by 2030."

The move will lead to a sharp increase in demand for ART medicines, which are typically given as a three-drug cocktail to avoid the risk of the virus developing resistance.

Major suppliers of HIV drugs include Gilead Sciences, ViiV Healthcare, which is majority-owned by GlaxoSmithKline, and multiple Indian generic manufacturers.

The medical charity Medecins Sans Frontieres (Doctors Without Borders) welcomed the WHO's "treat-all" plan, which it believes will prevent many HIV-positive people in poorer countries from falling through the treatment net.

MSF said its experience showed that a third of people who were diagnosed with HIV, but not eligible to start treatment, never returned to the clinic.

The charity also warned that making the new recommendation a reality would require dramatically increased financial support from donors and governments.

The WHO estimates that by 2020 low- and lower-middle income countries will need $18.4 billion annually for the expanded HIV fight. However, fast-tracking the response should yield economic returns of $15 per dollar invested, based on improved health and infections averted.

Since it began spreading 30 years ago, AIDS has killed around 40 million people worldwide.

 

It’s Time to Stand Up for Science

If you enjoyed this article, I’d like to ask for your support. Scientific American has served as an advocate for science and industry for 180 years, and right now may be the most critical moment in that two-century history.

I’ve been a Scientific American subscriber since I was 12 years old, and it helped shape the way I look at the world. SciAm always educates and delights me, and inspires a sense of awe for our vast, beautiful universe. I hope it does that for you, too.

If you subscribe to Scientific American, you help ensure that our coverage is centered on meaningful research and discovery; that we have the resources to report on the decisions that threaten labs across the U.S.; and that we support both budding and working scientists at a time when the value of science itself too often goes unrecognized.

In return, you get essential news, captivating podcasts, brilliant infographics, can't-miss newsletters, must-watch videos, challenging games, and the science world's best writing and reporting. You can even gift someone a subscription.

There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission.

Thank you,

David M. Ewalt, Editor in Chief, Scientific American

Subscribe